SE9901272D0 - New improved formulation - Google Patents
New improved formulationInfo
- Publication number
- SE9901272D0 SE9901272D0 SE9901272A SE9901272A SE9901272D0 SE 9901272 D0 SE9901272 D0 SE 9901272D0 SE 9901272 A SE9901272 A SE 9901272A SE 9901272 A SE9901272 A SE 9901272A SE 9901272 D0 SE9901272 D0 SE 9901272D0
- Authority
- SE
- Sweden
- Prior art keywords
- new improved
- improved formulation
- pharmaceutical formulations
- bisphosphonate
- osteoporosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Abstract
The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an additive consisting of one or more absorption enhancing agents. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901272A SE9901272D0 (en) | 1999-04-09 | 1999-04-09 | New improved formulation |
KR1020017012793A KR20010104389A (en) | 1999-04-09 | 2000-04-06 | A Pharmaceutical Formulation Comprising an Bisphosphonate and an Additive Agent Providing an Enhanced Absorption of the Bisphosphonate |
NZ514478A NZ514478A (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
EP00921288A EP1171097A1 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
JP2000610444A JP2002541185A (en) | 1999-04-09 | 2000-04-06 | Pharmaceutical formulations comprising bisphosphonates and additives providing enhanced absorption of bisphosphonates |
CA002364659A CA2364659A1 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
PCT/SE2000/000664 WO2000061111A1 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
AU41619/00A AU4161900A (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
IL14550600A IL145506A0 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
ZA200108260A ZA200108260B (en) | 1999-04-09 | 2001-10-08 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate. |
NO20014895A NO20014895L (en) | 1999-04-09 | 2001-10-08 | Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901272A SE9901272D0 (en) | 1999-04-09 | 1999-04-09 | New improved formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9901272D0 true SE9901272D0 (en) | 1999-04-09 |
Family
ID=20415159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9901272A SE9901272D0 (en) | 1999-04-09 | 1999-04-09 | New improved formulation |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1171097A1 (en) |
JP (1) | JP2002541185A (en) |
KR (1) | KR20010104389A (en) |
AU (1) | AU4161900A (en) |
CA (1) | CA2364659A1 (en) |
IL (1) | IL145506A0 (en) |
NO (1) | NO20014895L (en) |
NZ (1) | NZ514478A (en) |
SE (1) | SE9901272D0 (en) |
WO (1) | WO2000061111A1 (en) |
ZA (1) | ZA200108260B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
EP1267890A2 (en) | 2000-04-07 | 2003-01-02 | The Board of Regents of The University of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
CN1180846C (en) * | 2000-05-05 | 2004-12-22 | 霍夫曼-拉罗奇有限公司 | Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts |
CN1492763B (en) * | 2001-03-01 | 2012-05-23 | 艾米斯菲尔技术有限公司 | Compositions for delivering bisphosphonates |
WO2003003999A2 (en) * | 2001-07-02 | 2003-01-16 | Elan Corporation, Plc. | Delivery of a bioactive material |
KR100642961B1 (en) | 2002-05-10 | 2006-11-10 | 에프. 호프만-라 로슈 아게 | Bisphosphonic acid for the treatment and prevention of osteoporosis |
PT1790347E (en) | 2002-12-20 | 2015-02-05 | Hoffmann La Roche | High dose ibandronate formulation |
CA2513543A1 (en) * | 2003-01-17 | 2004-08-05 | Teva Pharmaceutical Industries Ltd. | Risedronate sodium having a very low content of iron |
GB0310919D0 (en) * | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
WO2004110458A1 (en) * | 2003-05-16 | 2004-12-23 | Board Of Regents, The University Of Texas System | Phenothiazine enantiomers as agents for the prevention of bone loss |
US7645459B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
CN1956706A (en) * | 2004-05-24 | 2007-05-02 | 宝洁公司 | Enteric solid oral dosage form of bisphosphonate containing a chelating agent |
US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
KR100815040B1 (en) * | 2005-01-31 | 2008-03-18 | 주식회사종근당 | Pharmaceutical compositions containing bisphosphonate for improving oral absorption |
NO20053519L (en) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Use of compounds comprising fatty acids |
CA2648594C (en) * | 2006-04-07 | 2012-10-16 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
GB0616794D0 (en) | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
US20090280169A1 (en) | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
CA2731769C (en) | 2008-07-21 | 2013-09-10 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
KR101631243B1 (en) * | 2009-05-13 | 2016-06-17 | 신일제약주식회사 | Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
NO2459176T3 (en) | 2009-07-31 | 2018-02-24 | ||
FR2954320B1 (en) | 2009-12-17 | 2012-06-15 | Cll Pharma | SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
KR20120105738A (en) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | An enteric-coated oral formulation |
JP5874545B2 (en) * | 2011-06-20 | 2016-03-02 | アステラス製薬株式会社 | Pharmaceutical composition for oral administration |
JP7211704B2 (en) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | A tablet containing a GLP-1 agonist and an enteric coating |
WO2017007777A2 (en) * | 2015-07-06 | 2017-01-12 | Zhengxin Dong | NOVEL FORMULATIONS OF PTHrP ANALOGUE |
EP3455229B1 (en) * | 2016-05-13 | 2021-03-24 | Thar Pharma LLC | Novel crystalline forms |
US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
CN112972400A (en) * | 2021-03-09 | 2021-06-18 | 华侨大学 | Rapidly disintegrable minodronic acid granules and preparation method thereof |
KR20240013402A (en) * | 2022-07-22 | 2024-01-30 | 주식회사 아이큐어비앤피 | Oral pharmaceutical composition comprising teriparatide for preventing or treating osteoporosis and method for preparing the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
EP0550385A1 (en) * | 1991-12-19 | 1993-07-07 | Ciba-Geigy Ag | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers |
TW237386B (en) * | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
SE501389C2 (en) * | 1992-04-24 | 1995-01-30 | Leiras Oy | Pharmaceutical preparation and process for its preparation |
AU687744B2 (en) * | 1993-05-15 | 1998-03-05 | Riemser Arzneimittel Ag | More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent |
IL118422A0 (en) * | 1995-06-02 | 1996-09-12 | Merck & Co Inc | Use of alendronate for the prevention of osteoporosis |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
FI109088B (en) * | 1997-09-19 | 2002-05-31 | Leiras Oy | Tablet and process for its preparation |
SE9703691D0 (en) * | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-04-09 SE SE9901272A patent/SE9901272D0/en unknown
-
2000
- 2000-04-06 WO PCT/SE2000/000664 patent/WO2000061111A1/en active Search and Examination
- 2000-04-06 AU AU41619/00A patent/AU4161900A/en not_active Abandoned
- 2000-04-06 JP JP2000610444A patent/JP2002541185A/en active Pending
- 2000-04-06 NZ NZ514478A patent/NZ514478A/en unknown
- 2000-04-06 CA CA002364659A patent/CA2364659A1/en not_active Abandoned
- 2000-04-06 IL IL14550600A patent/IL145506A0/en unknown
- 2000-04-06 KR KR1020017012793A patent/KR20010104389A/en not_active Application Discontinuation
- 2000-04-06 EP EP00921288A patent/EP1171097A1/en not_active Withdrawn
-
2001
- 2001-10-08 NO NO20014895A patent/NO20014895L/en not_active Application Discontinuation
- 2001-10-08 ZA ZA200108260A patent/ZA200108260B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200108260B (en) | 2003-03-26 |
NO20014895D0 (en) | 2001-10-08 |
JP2002541185A (en) | 2002-12-03 |
NZ514478A (en) | 2004-01-30 |
KR20010104389A (en) | 2001-11-24 |
CA2364659A1 (en) | 2000-10-19 |
AU4161900A (en) | 2000-11-14 |
WO2000061111A1 (en) | 2000-10-19 |
IL145506A0 (en) | 2002-06-30 |
EP1171097A1 (en) | 2002-01-16 |
NO20014895L (en) | 2001-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9901272D0 (en) | New improved formulation | |
SE9703691D0 (en) | Pharmaceutical compositions | |
ATE232874T1 (en) | PROSTAGLANDIN CONJUGATES FOR THE TREATMENT OF BONE DISEASES | |
BR0016058A (en) | Phosphonate Compounds | |
TR200101103T2 (en) | Controlled release pharmaceutical formulations containing CGMP PDE-Inhibitor | |
PL1663185T3 (en) | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss | |
SI1509232T1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
PT1235799E (en) | POLYMORIC FORM OF ATORVASTATIN-CALCIUM | |
HUP0004271A2 (en) | Compositions comprising amylin or amylin agonist for treating obesity | |
DK0679393T3 (en) | Pharmaceutical composition for the treatment of osteoporosis containing xanthohumol | |
ATE253351T1 (en) | DEODORIZING PREPARATIONS CONTAINING WATER-SOLUBLE -(1,3)-GLUCANS | |
WO2001030333A3 (en) | Tissue factor antagonists and methods of use thereof | |
TR199902703T2 (en) | Protease inhibitors. | |
ATE277026T1 (en) | NAPHTHYL COMPOUNDS, COMPOSITIONS AND METHODS | |
DE69905214T2 (en) | Agents for the treatment of osteoporosis | |
AU2003211610A1 (en) | Pharmaceutical compositions for the treatment or prevention of osteoporosis | |
TWI262791B (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
DK0977871T3 (en) | Neurotrypsin | |
ATE263566T1 (en) | MEDICAL COMPOSITIONS FOR THE TREATMENT OF BONE DAMAGE IN MULTIPLE MYELOMA | |
ATE245637T1 (en) | BENZOTHIOPHENE COMPOUNDS, PREPARATIONS AND METHODS | |
ATE244230T1 (en) | DIHYDROBENZOFLUORENE COMPOUNDS, INTERMEDIATE PRODUCTS, COMPOSITIONS AND METHOD | |
FR2783518B1 (en) | LTA4 HYDROLASE INHIBITORS | |
MXPA03006468A (en) | Compositions for prevention or treatment of hepatopathy. | |
TWI226833B (en) | Pharmaceutical composition for inhibiting bone resorption | |
IL122883A0 (en) | Pharmaceutical compositions for the treatment of dyskinesias |